Data support adding suprachoroidal injection to anti-VEGF for RVO
Additive approach augments results of intravitreal anti-VEGF with encouraging safety profile
The safety review showed no cases of cataract exacerbation in the combination therapy group. Two eyes (8.7%) developed IOP ≥30 mm Hg, and both were controlled on topical medication.
“Because this was a small study with short follow-up, we would not expect to see any significant corticosteroid-induced cataract changes,” Dr. Brown said. “The safety of suprachoroidal triamcinolone acetonide will receive further scrutiny in trials of its use in uveitis that are investigating multiple doses and over longer follow-up.”